Übersicht – Medikamentöse Therapie des Pankreaskarzinoms

Bei der Therapieentscheidung werden das Alter und der allgemeine Gesundheitszustand des Patienten mit berücksichtigt, das entscheidende Kriterium ist jedoch das Stadium der Tumorerkrankung.

• Literatur

• 1 Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreastic cancer: a randomized control trial. JAMA 2007; 297: 267-277
• 2 Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081
• 3 http://conko-studien.de/studien/65
• 4 http://conko-studien.de/studien/64
• 5 Burris III HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
• 6 Poplin E, Feng Y, Berlin J et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27: 3778-3785
• 7 Heiss MM, Murawa P, Koralewski P et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II / III trial. Int J Cancer 2010; 127: 2209-2221
• 8 Davidson W, Ash S, Capra S et al. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr 2004; 23: 239-247
• 9 Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966
• 10 Conroy T, Desseigne F, Ychou M et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU / leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010; 28: 15s (Suppl. Abstr. 4010)
• 11 Pelzer U, Kubica K, Stieler J et al. A randomized trial in patients wich gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26 (Suppl. Abstr. 4508)